X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting

Stock Information for X4 Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About X4 Pharmaceuticals Inc.

X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.